Holen Sie sich die Stockscreener-App
3.1152
1.42%
-0.0448
Handel nachbörslich:
3.12
0.0048
+0.15%
Schlusskurs vom Vortag:
$3.16
Offen:
$3.1
24-Stunden-Volumen:
12,066
Relative Volume:
0.30
Marktkapitalisierung:
$16.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.0214
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
-1.73%
1M Leistung:
+8.54%
6M Leistung:
-37.94%
1J Leistung:
-61.92%
1-Tages-Spanne:
$3.05
$3.1893
1-Wochen-Bereich:
$3.00
$3.60
52-Wochen-Spanne:
$2.6838
$11.79
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.1152 | 16.96M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - marketscreener.com
Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan
Lipocine’s Partner Files New Drug Submission in Canada - TipRanks
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World
Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks
Q2 Earnings Forecast for Lipocine Issued By HC Wainwright - Defense World
HC Wainwright Upgrades Lipocine (NASDAQ:LPCN) to Strong-Buy - Defense World
Lipocine’s (LPCN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Lipocine (LPCN) Receives Buy Rating from HC Wainwright & Co. | L - GuruFocus
Lipocine (LPCN) Gains Analyst Confidence with Buy Rating and Fut - GuruFocus
Lipocine Gains Bullish New Coverage, With Stock (LPCN) Down 30% YTD - AskTraders.com
Lipocine (LPCN) Gains Analyst Confidence with Buy Rating and Future Prospects | LPCN Stock News - GuruFocus
Lipocine (NASDAQ:LPCN) Share Price Crosses Above Fifty Day Moving Average – Here’s Why - Defense World
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - Nasdaq
Lipocine’s LPCN 1148 Gains Fast Track Designation - TipRanks
Lipocine (NASDAQ:LPCN) Share Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - Longview News-Journal
Lipocine to Present at A.G.P. Healthcare Showcase - TipRanks
Lipocine Reveals Next-Gen Oral Drug Delivery Platform at Major Healthcare ConferenceKey Developments Expected - Stock Titan
Lipocine Updates Corporate Presentation for Stakeholders - TipRanks
Lipocine To Present At H.C. Wainwright Annual Neuropsychiatry Virtual Conference - Barchart.com
Lipocine: Q1 Earnings Snapshot - CT Insider
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 30, 2025 - marketscreener.com
Lipocine Reports Q1 2025 Financial Results - TipRanks
Lipocine Inc. SEC 10-Q Report - TradingView
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - Morningstar
Renaissance Technologies LLC Sells 4,300 Shares of Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine announces license and supply agreement with Ache - TipRanks
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - Eagle-Tribune
Lipocine Partners with Aché for TLANDO® in Brazil - TipRanks
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock Ne - GuruFocus
Lipocine partners with Aché to market TLANDO in Brazil By Investing.com - Investing.com Canada
Lipocine partners with Aché to market TLANDO in Brazil - Investing.com
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock News - GuruFocus
Lipocine Targets Booming Brazil Testosterone Market with Exclusive TLANDO License Deal as Growth Hits 34% - Stock Titan
Lipocine Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Boosts Holdings in Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):